Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

被引：58

作者：

Choueiri, Toni K.

Albiges, Laurence

Haanen, John B. A. G.

Larkin, James M. G.

Uemura, Motohide

Pal, Sumanta K.

Gravis, Gwenaelle

Campbell, Matthew T.

Penkov, Konstantin

Lee, Jae-Lyun

Ching, Keith A.

Mu, Xinmeng Jasmine

Wang, Xiao

Zhang, Weidong

Wang, Jing

Chudnovsky, Aleksander

di Pietro, Alessandra

Robbins, Paul B.

Motzer, Robert J.

机构：

[1] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[3] Inst Gustave Roussy, Villejuif, France

[4] Netherlands Canc Inst, Amsterdam, Netherlands

[5] Royal Marsden NHS Fdn Trust, London, England

[6] Osaka Univ Hosp, Osaka, Japan

[7] City Hope Comprehens Canc Ctr, Duarte, CA USA

[8] Inst Paoli Calmettes, Marseille, France

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[10] Private Med Inst Euromedservice, St Petersburg, Russia

[11] Univ Ulsan, Coll Med, Seoul, South Korea

[12] Pfizer Inc, San Diego, CA USA

[13] Pfizer Inc, Cambridge, MA USA

[14] Pfizer SRL, Milan, Italy

[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.101

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

101

引用

页数：2